Hikal completes EDQM inspection at its Bangalore’s manufacturing facility

30 Jul 2014 Evaluate

Hikal has successfully completed an inspection by European Directorate for the Quality of Medicines (EDQM) at its manufacturing facility at Bangalore. The primary focus of the inspection was the adherence to compliance and implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal products in the European Union.

The inspection concluded that the company operated in accordance with the rules and regulations of the governing authorities based in the European Union and Hikal’s adherence to the highest standards of product quality and global regulatory compliance procedures as part of its fundamental value system. The successful completion of this audit is a positive reflection of company’s people, systems and procedures and commitment to Company's global customer base.

Hikal is a provider of solutions & reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection, Animal health, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for its customers in the United States, Europe and Japan.

Hikal Share Price

390.75 3.10 (0.80%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.